Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.660
-0.040 (-0.85%)
At close: Feb 27, 2026, 4:00 PM EST
4.630
-0.030 (-0.64%)
After-hours: Feb 27, 2026, 6:05 PM EST
Arbutus Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Arbutus Biopharma stock has a target of 5.00, which predicts an increase of 7.30% from the current stock price of 4.66.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Arbutus Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +7.30% | Nov 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +7.30% | Aug 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +7.30% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +7.30% | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +7.30% | Nov 20, 2024 |
Financial Forecast
Revenue This Year
13.90M
from 6.17M
Increased by 125.30%
Revenue Next Year
1.02M
from 13.90M
Decreased by -92.66%
EPS This Year
-0.19
from -0.38
EPS Next Year
-0.16
from -0.19
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.4M | 1.1M | |
| Avg | 13.9M | 1.0M | |
| Low | 13.3M | 980,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 133.1% | -92.4% | |
| Avg | 125.3% | -92.7% | |
| Low | 115.4% | -93.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.19 | -0.17 | |
| Avg | -0.19 | -0.16 | |
| Low | -0.19 | -0.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.